CSIMarket
 
Tenax Therapeutics Inc   (TENX)
Other Ticker:  
 
 
Price: $3.7500 $-0.07 -1.832%
Day's High: $3.8965 Week Perf: -6.48 %
Day's Low: $ 3.69 30 Day Perf: -10.61 %
Volume (M): 94 52 Wk High: $ 61.20
Volume (M$): $ 353 52 Wk Avg: $22.47
Open: $3.80 52 Wk Low: $3.69



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 0
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 7
 Cash Flow (TTM) (Millions $) 7
 Capital Exp. (TTM) (Millions $) 0

Tenax Therapeutics Inc
Tenax Therapeutics, Inc. is a biopharmaceutical company specializing in the development and commercialization of products for the critical care market. The company is focused on addressing the needs of patients suffering from diseases and conditions with significant unmet medical need. Tenax Therapeutics is committed to developing innovative therapies that improve patient outcomes and quality of life. The company's key product candidate is levosimendan, a calcium sensitizer and potassium channel activator, which is being developed for use in treating patients with pulmonary hypertension associated with heart failure and low cardiac output syndrome after cardiac surgery. Tenax Therapeutics aims to become a leader in the critical care market by developing effective and safe therapies that optimize patient care.


   Company Address: 101 Glen Lennox Drive Chapel Hill 27517 NC
   Company Phone Number: 855-2100   Stock Exchange / Ticker: NASDAQ TENX
   TENX is expected to report next financial results on March 29, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Management Announcement

Tenax Therapeutics Expands Global Rights to Revolutionary Treatment for Pulmonary Hypertension

Published Tue, Feb 20 2024 1:30 PM UTC



In a major breakthrough for the field of cardiovascular and pulmonary medicine, Tenax Therapeutics, a Phase 3, development-stage pharmaceutical company, has announced a significant expansion of its global development, commercial, and intellectual property rights to a life-changing treatment known as levosimendan. This development holds immense promise for patients ...

Clinical Study

Tenax Therapeutics Launches Groundbreaking Phase 3 Study Evaluating Novel Treatment for Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Published Thu, Feb 8 2024 1:01 AM UTC

In a major stride towards combatting the debilitating heart condition known as Heart Failure with Preserved Ejection Fraction (HFpEF), Tenax Therapeutics has successfully enrolled the first patient in their groundbreaking Phase 3 study. The clinical trial, named LEVEL, aims to evaluate the effectiveness of TNX-103, an oral medication based on levosimendan, in treating the as...

Shares

Tenax Therapeutics Executes Reverse Stock Split to Foster Cardiovascular Market Expansion

Published Fri, Dec 29 2023 1:30 PM UTC



Chapel Hill-based specialty pharmaceutical company Tenax Therapeutics, Inc. (Nasdaq: TENX) has recently announced a significant strategic move that will reshape its capital structure and potentially open new avenues for growth. The company is set to execute a reverse stock split at a ratio of 1-for-80, aimed at strengthening its position in addressing the unmet med...

Management Changes

Tenax Therapeutics Welcomes Dr. Javed Butler to Advisory Board as Strong Q3 2023 ROA Performance Points to Promising Future

Published Fri, Nov 17 2023 1:30 PM UTC



Tenax Therapeutics, a leading specialty pharmaceutical company catering to unmet medical needs in cardiovascular and pulmonary diseases, has recently appointed renowned cardiologist and academician, Dr. Javed Butler, to its PH-HFpEF Scientific Advisory Board (SAB). This strategic move aims to enhance the company's expertise and drive innovation in the field. Additi...

Tenax Therapeutics Inc

Tenax Therapeutics Inc Reveals Decrease in Operating Surplus for Q3 2023, Highlighting the Evolving Landscape of Major Pharmaceutical Preparations Market

Tenax Therapeutics Inc Posts Operating Surplus of $2.117 Million in Q3 2023
In the world of major pharmaceutical preparations, it's not only the industry leaders that are making headlines. Smaller companies like Tenax Therapeutics Inc are also reporting their financial numbers, providing investors with valuable insights into their performance.
Tenax Therapeutics Inc recently announced an operating surplus of $2.117379 million for the third quarter of 2023. While the company has yet to disclose its revenue figures, it is crucial to understand the context of this latest achievement. By comparing it to the company's performance in the third quarter of 2022, we can gain a better understanding of its progress. Back then, Tenax Therapeutics Inc had reported an operating surplus of $2.917488 million, with a bottom-line of $1.972 million.
However, it is important to note that the current numbers represent a decrease of 32.39 basis points from the third quarter of 2022. Operating earnings fell by 27.42% to $2.117379 million, resulting in a 0% operating margin for Tenax Therapeutics Inc in Q3 2023 compared to 0% in Q3 2022.
Looking ahead, investors can anticipate Tenax Therapeutics Inc's next financial earnings report, scheduled for March 29, 2024. This will provide further insights into the company's financial performance and its future direction.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com